Treatment with pembrolizumab and the antibody-drug conjugate (ADC) sacituzumab govitecan improved progression-free survival (PFS) in patients with PD-L1-positive locally advanced or metastatic ...
Overall survival was statistically significantly improved in adults treated with tislelizumab/chemotherapy compared with placebo/chemotherapy. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results